View in EDS

P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.

Saved in:
Bibliographic Details
Title: P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial.
Authors: Fernández Montes, A.1 (AUTHOR), Martinez Lago, N.2 (AUTHOR), De la Cámara Gómez, J.3 (AUTHOR), Covela Rúa, M.4 (AUTHOR), Cousillas Castiñeiras, A.5 (AUTHOR), Gonzalez Villarroel, P.6 (AUTHOR), Méndez Méndez, J.7 (AUTHOR)
Source: Annals of Oncology. 2019 Supplement, Vol. 30, piv23-iv24. 2p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdz155.088